The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Exercise of Options

21 Sep 2011 15:30

RNS Number : 6816O
Alliance Pharma PLC
21 September 2011
 



For immediate release

21 September 2011

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Exercise of Share Options

 

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that following the exercise of employee share options on 21 September 2011, application has been made by Alliance for a further 55,250 ordinary shares of 1 pence each in the Company ("Ordinary Shares") to be admitted to trading on AIM.

 

It is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 27 September 2011.

 

Following the exercise of the options, Alliance will have 240,105,034 Ordinary Shares in issue.

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0) 1249 466966

John Dawson, Chief Executive Officer

Richard Wright, Finance Director

www.alliancepharma.co.uk

Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court / Jessica Fontaine

Numis Securities Limited

+ 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Oliver Cardigan

Corporate Broking: David Poutney

 

Notes to editors:

 

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

 

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

 

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEPGURPBUPGGCG

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.